More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$11.33B
EPS
-0.08
P/E ratio
--
Price to sales
3.11
Dividend yield
--
Beta
0.211732
Previous close
$57.99
Today's open
$57.95
Day's range
$57.33 - $58.65
52 week range
$49.26 - $70.98
show more
CEO
Alexander Hardy
Employees
3221
Headquarters
San Rafael, CA
Exchange
Nasdaq Global Select
Shares outstanding
193694734
Issue type
Common Stock
Healthcare
Biotechnology & Life Sciences
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 17, 2026

BioMarin Pharmaceutical Sees $2.6 Billion Sales Potential in Amicus Drugs as VOXZOGO Expansion Looms
BioMarin Pharmaceutical NASDAQ: BMRN expects growth from its acquired rare disease treatments, an expanded market for VOXZOGO and a pipeline that could deliver patient data in 2027, Chief Executive Officer Alexander Hardy said at the UBS Global Biopharma Conference.
MarketBeat • Nov 16, 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at UBS Global Biopharma Conference 2026 Transcript
Seeking Alpha • Nov 16, 2026

BioMarin Pharmaceutical Hits $1 Billion Revenue Milestone, Advances Rare-Disease Pipeline
BioMarin Pharmaceutical NASDAQ: BMRN is advancing a group of newly acquired rare-disease drug candidates while integrating Amicus Therapeutics and working to reduce debt, executives said during a company discussion.
MarketBeat • Nov 12, 2026

BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
BioMarin Pharmaceutical Inc. (BMRN) Presents at Stifel 2026 Healthcare Conference 2026 Transcript
Seeking Alpha • Nov 12, 2026

BioMarin to Participate in Upcoming Investor Conferences
Stifel Healthcare Conference, November 11 at 3:20 pm EST UBS Global Biopharma Conference, November 16 at 9:20 am GMT Jefferies Global Healthcare Conference, November 17 at 11:30 am GMT SAN RAFAEL, Calif., Nov. 4, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will present at upcoming investor conferences in November.
PRNewsWire • Nov 4, 2026

BioMarin: Better Risk-Reward Ahead Of Three FDA Decisions
BioMarin's lower valuation and broader commercial portfolio now offer a better entry point compared with my previous Hold rating on this name. Voxzogo's potential hypochondroplasia expansion is a nice growth catalyst, and a full approval would further strengthen BMRN's existing achondroplasia franchise. Their Amicus acquisition also brings new revenue sources, though I reckon it remains to be seen if it fully justifies the debt required to finance the transaction.
Seeking Alpha • Nov 4, 2026

BioMarin Pharmaceutical Inc. (BMRN) Q3 2026 Earnings Call Transcript
BioMarin Pharmaceutical Inc. ( BMRN ) Q3 2026 Earnings Call November 2, 2026 4:30 PM EST Company Participants Traci McCarty - Group Vice President Alexander Hardy - President, CEO & Director Cristin Hubbard - Executive VP & Chief Commercial Officer Gregory Friberg - Executive VP and Chief Research & Development Officer Brian Mueller - CFO & Executive VP of Finance Conference Call Participants Sean Laaman - Morgan Stanley, Research Division Eliana Merle - Barclays Bank PLC, Research Division Adithya Jayaraman - Evercore Inc. Paul Matteis - Stifel, Nicolaus & Company, Incorporated, Research Division Alexandria Hammond - Wolfe Research, LLC Rakesh Kumar Joon Lee Olivia Brayer - Cantor Fitzgerald & Co., Research Division Christopher Raymond - Raymond James & Associates, Inc., Research Division Joseph Schwartz - Leerink Partners LLC, Research Division Presentation Operator Hello, everyone. Thank you for joining us, and welcome to the BioMarin Third Quarter 2026 Conference Call.
Seeking Alpha • Nov 3, 2026

BioMarin Pharmaceutical Q3 Earnings Call Highlights
BioMarin Pharmaceutical NASDAQ: BMRN reported third-quarter revenue above $1 billion for the first time, driven by growth across its rare-disease portfolio and contributions from acquired Amicus Therapeutics products. The company said revenue increased 32% year over year, while its metabolic conditions business grew 44%.
MarketBeat • Nov 3, 2026

BioMarin Reports Third Quarter 2026 Financial and Operating Results
Third Quarter 2026 Total Revenues Increased 32% Y/Y to $1.025 billion; Growth Driven by 44% Increase in Metabolic Conditions Y/Y, and 12% Increase in Skeletal Conditions Y/Y Updates Full-year 2026 Guidance to Reflect Order Timing Uncertainty and Impact of Two Acquired In-process Research and Development (IPR&D) Charges Recently Announced the Addition of a New Investigational Fabry Asset to Clinical Portfolio PDUFA Action Date of May 30, 2027 for VOXZOGO® for the Treatment of Hypochondroplasia (HCH) Conference Call and Webcast Scheduled Today at 4:30 p.m. ET SAN RAFAEL, Calif.
PRNewsWire • Nov 2, 2026

¹ Disclosures

Open an M1 investment account to buy and sell BioMarin Pharmaceutical Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.